Epilepsia Open

Papers
(The H4-Index of Epilepsia Open is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Risk of COVID‐19 infection and seizure exacerbation among patients with epilepsy during the peak of Omicron wave83
A companion to the preclinical common data elements for proteomics, lipidomics, and metabolomics data in rodent epilepsy models. A report of the TASK3‐WG4 omics working group of the ILAE/AES joint tra78
Microglia and status epilepticus in the immature brain58
Total posterior quadrant disconnection for drug‐resistant epilepsy in children46
An interview with Ifrah Zawar, 2023 Epilepsia Open prize winner for clinical research42
Epilepsy following neonatal encephalopathy—Future directions38
Sudden unexpected death in epilepsy ( SUDEP ): Risk management of pediatric patients with epilepsy36
Alterations of apparent diffusion coefficient from ultra high b‐values in the bilateral thalamus and striatum in MRI‐negative drug‐resistant epilepsy34
Long‐term effectiveness and tolerability of ketogenic diet therapy in patients with genetic developmental and epileptic encephalopathy onset within the first 6 months of life32
Patient complexity, depression, and quality of life in patients with epilepsy at an epilepsy center in Japan30
Building a dashboard to inform policy and clinical practice using the Irish epilepsy electronic patient record: Towards a learning health system29
One‐year seizure freedom and quality of life in patients with drug‐resistant epilepsy receiving adjunctive vagus nerve stimulation in Japan29
Incorporation bias in clinical prediction models for epilepsy27
Intestinal microbiome alterations in pediatric epilepsy: Implications for seizures and therapeutic approaches27
Characterization of low‐grade epilepsy‐associated tumor from implanted stereoelectroencephalography electrodes25
Effectiveness of perampanel as the only add‐on: Retrospective, multicenter, observational real‐life study on epilepsy patients25
Longitudinal hippocampal diffusion‐weighted imaging and T2 relaxometry demonstrate regional abnormalities which are stable and predict subfield pathology in temporal lobe epilepsy25
Key steps and barriers in the journey of patients with epilepsy through the National Healthcare System in Spain: The EPIPASS qualitative study24
Assessment of tau phosphorylation and β‐amyloid pathology in human drug‐resistant epilepsy24
MonoPER study: Effectiveness and tolerability of PERampanel in monotherapy in real‐world after 12 months of treatment23
Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first‐line add‐on therapies for seizures in Dravet syndrome: A network meta‐analysis23
Ex‐SPECTing success: Predictors of successful SPECT radiotracer injection during presurgical video‐EEG admissions23
Efficacy and Safety of adjunctive Perampanel in a prospective, real‐world, Phase IV study in Indian patients aged ≥12 years for Treatment of focal‐onset Epilepsy: Study 50823
0.17077112197876